MedPath

Randomized Study of Gonadotropin-releasing-hormone Agonist (GnRH-a) or Expectant Management for Endometriosis

Phase 4
Conditions
Endometriosis
Interventions
Drug: gonadotropin-releasing-hormone agonist (GnRHa) - Goserelin
Registration Number
NCT00654524
Lead Sponsor
Zhejiang University
Brief Summary

The purpose of this study is to identify the recurrent rate and pregnancy rate of advanced endometriosis after laparoscopic surgery plus GnRHa goserelin acetate treatment.

Detailed Description

In order to decrease endometriosis recurrence and enhance pregnancy rate after surgical therapy, it has been proposed to use a post-surgical gonadotropin-releasing-hormone agonist (GnRHa) treatment. Data on the short-term recurrence of advanced endometriosis is rare. Although operative treatment has resulted in increasing pregnancy rate comparing non surgery management for moderate to severe endometriosis, very few data of spontaneous pregnancy rate are available comparing GnRHa treatment or expectant management after surgery treatment. In this situation, the investigators conduct a prospective, randomized, controlled study to determine whether postoperative GnRHa (goserelin acetate) therapy for advanced endometriosis is effective in reducing endometriosis recurrence rate and improving reproductive outcome.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
60
Inclusion Criteria
  • Age >=18 years old
  • Normal menstruation for 3 months before enrollment (25-35 days)
  • Advanced endometriosis confirmed histologically (r-AFS score III-IV) with laparoscopy or laparotomy-pelvic pain and/or dysmenorrhea and/or dyspareunia
  • Agreement on the strict follow-up plan
  • Without previous hormonal treatment
  • Using nonhormonal method of contraception during this study
Exclusion Criteria
  • Serious heart diseases/pulmonary/liver/kidney diseases
  • Previous non-endometriosis relevant surgery possibly influence to abdominal or pelvic pain
  • Suspected malignancy in endometriosis
  • Coagulation disorders with hemorrhagic tendency
  • Pregnancy or lactation
  • Allergy to GnRHa
  • Previous ineffective treatment with GnRHa

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1gonadotropin-releasing-hormone agonist (GnRHa) - GoserelinPatients in this arm will be treated with goserelin depot-3.6mg plus add-back therapy.
Primary Outcome Measures
NameTimeMethod
The recurrent rate of advanced endometriosiswithin one year after surgery or GnRH-a management
Secondary Outcome Measures
NameTimeMethod
The pregnancy rate following laparoscopic surgery for advanced endometriosiswithin one year after surgery or GnRH-a treatment

Trial Locations

Locations (1)

Women's Hospital School Of Medicine Zhejiang University

🇨🇳

Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath